Adair Newhall

Domain Associates LLC (Domain Associates) is a venture capital firm founded in 1985. The firm is headquartered in Princeton, New Jersey.

Esprit Pharma, Inc. manufactures and supplies pharmaceutical products. The company offers SANCTURA, a treatment for over-active bladder and PRO-QUIN, a treatment for urinary tract infections. The company was founded in 2005 and is headquartered in East Brunswick, NJ.

ESP Pharma, Inc. produces pharmaceutical products. The company used to produce drug for acute-care hospital use and these drugs include therapeutics for high blood pressure and angina; one product, IV Busulfex, is used to prepare myelogenous for leukemia patients for bone marrow transplants. The company formulates its products to be delivered intravenously or by injection when oral administration is impossible. The company was founded in April, 2002 and was headquartered in Edison, NJ

Founded in 1998, Thomas Weisel Partners (TWP) is a broker/dealer headquartered in San Francisco with offices in New York City, Boston, Denver, Colorado and Palo Alto, California. The firm is a subsidiary of Thomas Weisel Partners Group, Inc. (Nasdaq: TWPG), a San Francisco-based investment banking firm. Their ultimate parent is Stifel Financial Corp. (NYSE: SF). TWP's investment banking, brokerage and equity research divisions serve emerging growth companies and institutional investors around the world. They are a member of the NYSE, the SIPC and FINRA. TWP specializes in the growth sectors of the economy with a particular focus on the consumer, energy, healthcare, Internet, media/telecommunications, metals/mining and technology sectors. Within the consumer sector, the firm focuses on: financial products, gaming/lodging, interactive market services, lifestyles/sports retailers, restaurants and hardlines and softlines retailing. TWP's global energy research is provided by analysts in three countries and covers the following trends: (1) fast-growing oil and natural gas producers in North America and worldwide (2) domestic and international energy service companies and (3) alternative energy technology and resource developers. Within the healthcare sector, TWP focuses on: biotechnology, diagnostics, healthcare information technology, pharmaceutical services, life science technology, medical devices and specialty pharmaceuticals. The firm's interest in the Internet, media and telecommunications sector include: Internet services, media, broadcasting and telecommunications services. Their focus within the metals and mining sector include: base metals, gold, precious metals and uranium. TWP's technology research focuses on: (1) applied technologies (2) communications components (3) core and wireless communications equipment (4) IP networking communications equipment (5) electronic supply chain (6) enterprise hardware (7) information and financial technology services (8) semiconductor capital equipment (9) broadline and specialty semiconductors (10) applications and communications software and (11) infrastructure software. TWP also provides value-added equities analysis across a variety of sectors including: industrials, financials, consumer, technology and healthcare.

Astute Medical, Inc. discovers and develops biomarkers for acute conditions and diseases. It develops protein biomarker-based diagnostics technology for high-risk medical conditions such as cerebrovascular injury, kidney injury, sepsis, abdominal pain, and acute coronary syndromes. The firm’s products include NephroCheck test and Astute140 meter kits. The company was founded by Christopher Richard Hibberd and Paul H. McPherson in 2007 and is headquartered in San Diego, CA.

Novalar Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It focuses on dental products. The company's OraVerse product (phentolamine mesylate) reverses the effects of local anesthetic with a vasoconstrictor and accelerates the return of normal sensation and function. The company was founded in 2000 and is headquartered in San Diego, CA.

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.